BSECompany Update1d ago · 1 Oct 2026, 09:35 pm
Extension of date of closing
Zydus Lifesciences Ltd · 532321
✦ AI SummaryJoint Venture
Zydus Lifesciences Ltd has extended the date of closing for its 50:50 joint venture with Sunshine Healthcare Lanka Limited, citing completion of condition precedents. The transaction is now expected to be completed by December 2026.
Analysis Scores
Earnings Impact2/10
Growth Catalyst6/10
Governance Concern1/10
Regulatory Risk2/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Updates on Joint Venture
Attachments (1)
📄pdf
Download →
148b3867-2b80-45fd-b3c5-49f44b585831.pdf
View document text
October 1, 2026
Listing Department Code: 532321 Listing Department Code: Zyduslife
BSE Limited National Stock Exchange Of India Limited
P J Towers, Dalal Street, Exchange Plaza, Bandra Kurla Complex,
Fort, Mumbai-400001 Bandra (E), Mumbai-400051
Re.: Update on Investment in the equity shares of Zydus Sunshine Lifesciences
(Private) Limited (“Zydus Sunshine”)
Ref.: 1. Intimation under regulation 30 of the SEBI (Listing Obligations and
Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular
dated January 30, 2026
2. Our earlier intimation dated June 26, 2026
Dear Sir / Madam,
In our earlier intimation dated June 26, 2026, Zydus Lifesciences Limited (“the Company”)
intimated about execution of Share Subscription and Shareholders’ Agreement (“SSSHA”)
with Sunshine Healthcare Lanka Limited (“Sunshine”) and Zydus Sunshine Lifesciences
(Private) Limited (“Zydus Sunshine”) to subscribe 50% of the total paid-up equity share
capital of Zydus Sunshine (“Subscription Shares”). It was also informed that post
subscription of the Subscription Shares, Zydus Sunshine shall become a 50:50 joint
venture of Zydus and Sunshine.
This is to inform that Zydus and Sunshine are still in the process of completing condition
precedents of the SSSHA. In view of the same, and as per the terms and conditions of the
SSSHA, the Company and Sunshine have mutually decided to extend the date of closing.
The Company and Sunshine have today, i.e. October 1, 2026, executed a letter to extend
the date of completion as above. In view of the same, the transaction is expected to be
completed by December 2026.
Please take the above on record.
Thanking you,
Yours faithfully,
For, Zydus Lifesciences Limited
Dhaval N. Soni
Company Secretary and Compliance Officer
Membership No. FCSS7063